Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015655:1-Methyl-4-phenylpyridinium; D000818:Animals; D001711:Biotransformation; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008928:Mitochondria / Q000378:metabolism; D008995:Monoamine Oxidase / Q000378:metabolism; D009243:NAD / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D011725:Pyridines / Q000378:metabolism / Q000494:pharmacology*; D011726:Pyridinium Compounds / Q000378:metabolism; D051381:Rats
D011725:Pyridines; D011726:Pyridinium Compounds; D009243:NAD; C044755:1-methyl-4-phenyl-2,3-dihydropyridinium; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008995:Monoamine Oxidase; D015655:1-Methyl-4-phenylpyridinium